Photo from wikipedia
Abstract Patients with Mycobacterium avium complex lung disease treated with amikacin liposome inhalation suspension (ALIS) at 2 clinics in the United States were surveyed to assess the frequency and management… Click to show full abstract
Abstract Patients with Mycobacterium avium complex lung disease treated with amikacin liposome inhalation suspension (ALIS) at 2 clinics in the United States were surveyed to assess the frequency and management of ALIS-associated respiratory adverse events. Most respondents experienced these events, but management through physician-guided measures (eg, bronchodilator use, oral rinses, and/or temporary dosing adjustments) resulted in symptomatic improvement.
Keywords:
amikacin liposome;
management;
respiratory adverse;
adverse events;
liposome inhalation;
inhalation suspension
Journal Title: Open Forum Infectious Diseases
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Open Forum Infectious Diseases
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!